ReviewNeurologia medico-chirurgica2015
Craniopharyngioma in Children: Long-term Outcomes.
Review in Neurologia medico-chirurgica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Lethally aggressive multiply recurrent adamantinomatous craniopharyngioma without histological malignancy: illustrative cases.Journal of neurosurgery. Case lessons · 2026Article
- Treatment Priorities in Craniopharyngioma: Perspectives of Survivors and Caregivers.Biomedicines · 2026Article
- Arginine Vasopressin Deficiency in Children with Craniopharyngioma and Cerebral Germ Cell Tumour: Two Sides of the Same Coin - Clinical and Radiological Features.Hormone research in paediatrics · 2025Article
- Article
- Feasibility, tolerability, and first experience of intracystic treatment with peginterferon alfa-2a in patients with cystic craniopharyngioma.Frontiers in oncology · 2024Article
- Shifting Strategies in the Treatment of Pediatric Craniopharyngioma.Current oncology reports · 2023Review
- Vision-related quality of life in patients with childhood-onset craniopharyngioma.Scientific reports · 2023Article
- Predictive Factors for Pediatric Craniopharyngioma Recurrence: An Extensive Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
- Radiotherapy-Induced Neurocognitive Dysfunction in Brain Tumor Survivors: Burden and Rehabilitation.Acta neurochirurgica. Supplement · 2023Article
- Risk factors for postresection shunting in children with suprasellar tumor: a retrospective analysis of 124 patients.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022Article
- Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience.Frontiers in neurology · 2022Article
- Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity.Obesity facts · 2020Article
- Clinical Characteristics of Pediatric Patients With Sellar and Suprasellar Lesions Who Initially Present With Central Diabetes Insipidus: A Retrospective Study of 55 Cases From a Large Pituitary Center in China.Frontiers in endocrinology · 2020Article
- Long-term visual outcomes of craniopharyngioma in children.Journal of neuro-oncology · 2018Article
- Gross Total Versus Subtotal Surgical Resection in the Management of Craniopharyngiomas.Allergy & rhinology (Providence, R.I.)Review
- Craniopharyngiomas in children - experience of consecutive 152 operated cases.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The survival rate for childhood craniopharyngioma has been improving, with more long-term survivors. Unfortunately it is rare for the patient to be normal, either from the disease itself or from the effects of treatment. Long-term survivors of childhood craniopharyngioma suffer a number of impairments, which include visual loss, endocrinopathy, hypothalamic dysfunction, cerebrovascular problems, neurologic and neurocognitive dysfunction. Pituitary insufficiency is present in almost 100%. Visual and hypothalamic dysfunction is common. There is a high risk of metabolic syndrome and increased risk of cerebrovascular disease, including stroke and Moyamoya syndrome. Cognitive, psychosocial, and emotional problems are prevalent. Finally, there is a higher risk of premature death among survivors of craniopharyngioma, and often this is not from tumor recurrence. It is important to consider craniopharyngioma as a chronic disease. There is no perfect treatment. The treatment has to be tailored to the individual patient to minimize dysfunction caused by tumor and treatments. So "cure" of the tumor does not mean a normal patient. The management of the patient and family needs multidisciplinary evaluation and should involve ophthalmology, endocrinology, neurosurgery, oncology, and psychology. Furthermore, it is also important to address emotional issues and social integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.